The role of cytochrome P450s in drug-induced liver disease

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 15-34

  Watkins, Paul B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012707159     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (103)

1. Gillette JR. Keynote address: man, mice, microsomes, metabolites, and mathematics 40 years after the revolution. Drug Metab Rev 1995; 27:1-44.
2. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995; 23:1624.
3. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharmaceut 1996; 24:461-473.
4. Nebert DW. Multiple forms of inducible drug-metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity. Mol Cell Biochem 1979; 27:27-46.
5. Benet LZ KD, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In JG Hardman, PB Molinoff, et al., eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996:3-29.
6. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32:210-258.
7. Tanaka E. Update: genetic polymorphism of drug metabolizing enzymes in humans. J Clin Pharm Ther 1999; 24:323-329.
8. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 1997; 37:269-296.
9. Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999; 20:12-24, 25137.
10. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
11. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
12. Chida M, Yokoi T, Kosaka Y, et al. Genetic polymorphism of CYP2D6 in the Japanese population. Pharmacogenetics 1999; 9:601-605.
13. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29:192-209.
14. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195-1202.
15. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-1030.
16. Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56:243-251.
17. Pelkonen O, Ratio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144:139-147.
18. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67:48-56.
19. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000; 53:88-93.
20. Morgan ET, Sewer MB, Iber H, et al. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Dispos 1998; 26:1232-1240.
21. Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin North Am 2000; 130-141.
22. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol (NY) 1997; 43:7-35.
23. Szklarz GD, Halpert JR. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 1998; 26:1179-1184.
24. Leichtman A, Watkins PB. The molecular basis of cyclosporin A metabolism, pharmacokinetics, and drug interactions. Organ Cell Transplant 1999; 2:177-182.
25. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450 [see comments]. J Clin Psychiatry 1998; 59: 19-27.
26. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369:11-23.
27. Lehmann JM, McKee DD, Watson MA, Wilson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102:1016-1023.
28. Blumberg B, Sabbagh W, Jr., Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998; 12:3195-3205.
29. Poellinger L. Mechanistic aspects—the dioxin (aryl hydrocarbon) receptor. Food Addit Con-tam 2000; 17:261-266.
30. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 1995; 23:1231-1241.
31. Xie W, Barwick JL, Downes M, et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000; 406:435-439.
32. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Bio-chem Pharmacol 1999; 57:465-480.
33. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Preclinical evaluation of drug-drug interaction potential: present studies of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 1997; 107:5-16.
34. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998; 38:461-499.
35. Streetman DS, Bertino JS, Jr., Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10:187-216.
36. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance [see comments]. Clin Cancer Res 2000; 6:1255-1258.
37. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18:2301-2308.
38. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53: 643-650.
39. Kharasch ED, Hankins DC, Jubert C, Thummel KE, Taraday JK. Lack of single-dose disul-firam effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metab Dispos 1999; 27:717-723.
40. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87:36-50.
41. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23:154-158.
42. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 1990; 29:651-663.
43. Kharasch ED, Hankins DC, Taraday JK. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metab Dispos 2000; 28:28-33.
44. Patten CJ, Thomas PE, Guy RL, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993; 6:511-518.
45. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to A-acetyl-^-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45: 1563-1569.
46. Chen W, Koenigs LL, Thompson SJ, et al. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol 1998; 11:295-301.
47. Sarich T, Kalhorn T, Magee S, et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62:21-28.
48. Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 2000; 67: 275-282.
49. Sinclair JF, Szakacs JG, Wood SG, et al. Acetaminophen hepatotoxicity precipitated by shortterm treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin, Biochem Pharmacol 2000; 59:445-454.
50. Walker BE, Kelleher J, Dixon MF, Losowsky MS. The effect of phenobarbitone pretreatment on paracetamol toxicity. Biomedicine 1973; 19:465-468.
51. Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy 2000; 20:229-233.
52. Bray GP, Harrison PM, O’Grady JG, Tredger JM, Williams R. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure [see comments]. Hum Exp Toxicol 1992; 11:265-270.
53. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995; 109:1907-1916.
54. Prescott LF, Critchley JA, Balali-Mood M, Pentland B, Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol 1981; 12:149-153.
55. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen’s metabolic pathways. Clin Pharmacol Ther 1984; 35:480-486.
56. Tomlinson B, Young RP, Ng MC, Anderson PJ, Kay R, Critchley JA. Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics. Eur J Clin Pharmacol 1996; 50:411-415.
57. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure [published erratum appears in Hepatology 1995; 22(6):1898]. Hepatology 1995; 22:767-773.
58. Sato C, Nakano M, Lieber CS. Prevention of acetaminophen-induced hepatotoxicity by acute ethanol administration in the rat: comparison with carbon tetrachloride-induced hepatoxicity. J Pharmacol Exp Ther 1981; 218:805-810.
59. Altomare E, Leo MA, Lieber CS. Interaction of acute ethanol administration with acetaminophen metabolism and toxicity in rats fed alcohol chronically. Alcoholism Clin Exp Res 1984; 8:405-408.
60. Banda PW, Quart BD. The effect of mild alcohol consumption on the metabolism of acetaminophen in man. Res Commun Chem Pathol Pharmacol 1982; 38:57-70.
61. Thummel KE, Slattery JT, Ro H, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000; 67:591-599.
62. Lieber C. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77:517-544.
63. Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 1995; 270:29632-29635.
64. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25:1165-1175.
65. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid [published erratum appears in Ann Intern Med 1991; 114(3):253] [see comments]. Ann Intern Med 1990; 113:799-800.
66. Crippin JS. Acetaminophen hepatotoxicity: potentiation by isoniazid. Am J Gastroenterol 1993; 88:590-592.
67. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair JF. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 1995; 322:516-520.
68. Kubota S, Lasker JM, Lieber CS. Molecular regulation of ethanol-inducible cytochrome P450-IIEI in hamsters. Biochem Biophys Res Commun 1988; 150:304-310.
69. Ronis MJ, Huang J, Crouch J, et al. Cytochrome P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. J Pharmacol Exp Ther 1993; 264:944-950.
70. Tsutsumi M, Lasker JM, Takahashi T, Lieber CS. In vivo induction of hepatic P4502E1 by ethanol: role of increased enzyme synthesis. Arch Biochem Biophys 1993; 304:209-218.
71. Takahashi T, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 1993; 17:236-245.
72. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47:1503-1508.
73. Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth 1991; 67:84-99.
74. Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993; 58:133-155.
75. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993; 23:1-20.
76. Spracklin DK, Thummel KE, Kharasch ED. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos 1996; 24:976-983.
77. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 347:1367-1371.
78. Kharasch ED, Hankins DC, Fenstamaker K, Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000; 55: 853-859.
79. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68:385-424.
80. Fontana RJ, Watkins PB. Genetic predisposition to drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:811-838.
81. Larrey PG. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26:12-21.
82. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25:1057-1064.
83. Satz N, Tauber M, Streuli R, Spycher MA, Maurer R. Perhexiline maleate-induced hepatitis. Hepato-Gastroenterology 1991; 38:314-316.
84. Watson RG, Olomu A, Clements D, Waring RH, Mitchell S, Elias E. A proposed mechanism for chlorpromazine jaundice—defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol 1988; 7:72-78.
85. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36:537-547.
86. 85a. Hofmann U, Eichelbaum M, Seefried S, Meese C. Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide, and (3-carboxymethyl-thio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine. Drug Metab Dispos 1990; 19:222-226.
87. Larrey D, Tinel M, Amouyal G, et al. Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients. J Hepatol 1989; 8:158-164.
88. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease [see comments.] JAMA 1994; 271:992-998.
89. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38:15-22.
90. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
91. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23: 1429-1435.
92. Fontana RJ, deVries TM, Woolf TF, et al. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer’s disease. Br J Clin Pharmacol 1998; 46:221-228.
93. Banks AT, Zimmerman HJ, Ishak KG, Hartner JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22:820-827.
94. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Brit J Clin Pharmacol 1998; 45:525-538.
95. Aithal GP, Leathart JBS, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10:511-518.
96. Bort R, Ponsoda X, Jover R, Gomez-Lechon MJ, Castell JV. Diclofenac toxicity to hepato-cytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 1999; 288:65-72.
97. Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26:23-30.
98. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyl-transferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26:1054-1066.
99. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50:573-582.
100. Knight TL, Scatchard KM, Van Pelt FN, Kenna JG. Sera from patients with halothane hepatitis contain antibodies to halothane-induced liver antigens which are not detectable by immu-noblotting [published erratum appears in J Pharmacol Exp Ther 1995 272(2):962]. Pharmacol Exp Ther 1994; 270:1325-1333.
101. Leeder JS, Riley RJ, Cook VA, Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992; 263: 360-367.
102. Leeder JS, Gaedigk A, Lu X, Cook VA. Epitone mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 1996; 49:234-243.
103. Goasduff T, Cederbaum AI. NADPH-dependent microsomal electron transfer increases degradation of CYP2E1 by the proteasome complex: role of reactive oxygen species. Arch Bio-chem Biophys 1999; 370:258-270.